Apricitabine

Drug Profile

Apricitabine

Alternative Names: (-)dOTC; ATC; AVX-754; BCH 10618; SPD-754

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Novita Healthcare
  • Class Antiretrovirals; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Feb 2016 Phase-III development is ongoing in Australia, Canada, USA, South America, Europe, Africa, Asia and Israel
  • 20 Jun 2013 Avexa signs binding term sheet with Link Healthcare relating to development, registration, and commercialisation of apricitabine worldwide (including North America and Europe)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top